Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Marín, José M.
  • dc.contributor.author Mateos, Luis
  • dc.contributor.author Roldán, Juan
  • dc.contributor.author Echave-Sustaeta, José M.
  • dc.contributor.author Pascual Guàrdia, Sergi, 1979-
  • dc.contributor.author Pardo, María V.
  • dc.contributor.author Velasco, Beatriz
  • dc.contributor.author Jones, C. Elaine
  • dc.contributor.author Kilbride, Sally
  • dc.contributor.author Lipson, David A.
  • dc.date.accessioned 2022-02-21T08:02:20Z
  • dc.date.available 2022-02-21T08:02:20Z
  • dc.date.issued 2020
  • dc.description.abstract Objectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA) and UMEC/VI (LAMA/LABA) in the treatment of patients with chronic obstructive disease (COPD). This study performs a subgroup analysis of the cohort from Spain in the IMPACT study. Materials and methods: In IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study (N = 10,355), patients ⩾40 years of age with COPD and ⩾1 moderate/severe exacerbations in the previous year were randomized 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg administered via the Ellipta inhaler. Here, we present a subgroup analysis of the 499 patients from Spain, included in the intent-to-treat (ITT) population in the study. Endpoint assessed included exposure-adjusted rate of moderate and severe exacerbations. Results: In the Spain cohort, the exposure-adjusted rate of on-treatment moderate/severe COPD exacerbations per year for FF/UMEC/VI was 1.31 versus 1.43 and 1.57 for FF/VI and UMEC/VI, respectively. No new adverse events were identified. The results are consistent with those observed in the overall ITT study population. Conclusion: In the Spain cohort of the IMPACT study, patients receiving triple therapy with FF/UMEC/VI had a lower exposure-adjusted rate of exacerbations compared with FF/VI and UMEC/VI, similar to the overall population. Study Title: A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=CTT116855/ https://clinicaltrials.gov/ct2/show/NCT02164513.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, et al. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Ther Adv Respir Dis. 2020 Jan-Dec; 14: 1753466620963021. DOI: 10.1177/1753466620963021
  • dc.identifier.doi http://dx.doi.org/10.1177/1753466620963021
  • dc.identifier.issn 1753-4658
  • dc.identifier.uri http://hdl.handle.net/10230/52530
  • dc.language.iso eng
  • dc.publisher SAGE Publications
  • dc.rights Copyright © The Author(s), 2020. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.keyword Chronic obstructive pulmonary disease (COPD)
  • dc.subject.keyword LABA
  • dc.subject.keyword LAMA
  • dc.subject.keyword Glucocorticoid
  • dc.subject.keyword Randomized clinical trial
  • dc.subject.keyword Triple therapy
  • dc.subject.keyword
  • dc.title Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)